Clinical Trial Update: Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating loncastuximab tesirine with durvalumab in various B-cell lymphomas was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Durvalumab (durvalumab)
• Loncastuximab tesirine (loncastuximab tesirine)

Snippet

Sponsor: ADC Therapeutics S.A. | Conditions: Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma | Phase 1 | Status: TERMINATED | Results posted: 2021-10-26